{"id":27533,"date":"2014-08-05T11:37:43","date_gmt":"2014-08-05T15:37:43","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=27533"},"modified":"2014-08-05T11:37:43","modified_gmt":"2014-08-05T15:37:43","slug":"arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533","title":{"rendered":"Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Sees Encouraging Advancements Of BELVIQ"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 08\/05\/2014 (wallstreetpr) \u2013\u00a0Biopharmaceutical company <b>Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)<\/b> disclosed that it had witnessed encouraging advancements of BELVIQ commercialization with the <a href=\"http:\/\/finance.yahoo.com\/news\/arena-pharmaceuticals-provides-corporate-reports-083000819.html\">prescriptions<\/a> recording a significant quarter-over-quarter growth. The company had also struck a marketing and supply deal in Israel for its BELVIQ.<\/p>\n<p style=\"text-align: justify;\"><b>Prescriptions Growth<\/b><\/p>\n<p style=\"text-align: justify;\">The company indicated that there was a quarter-over-quarter growth of 43% in total prescriptions of BELVIQ. Significantly, it has exceeded 10K mark on a weekly basis. It also said that IMS Health projected that about 110K prescriptions were filed for BELVIQ during the second quarter.<\/p>\n<p style=\"text-align: justify;\">Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)\u2019s Eisai registered net product sales of $9.9 million for BELVIQ, and it had completed its objective of increasing over 200 sales representatives in its unit of Metabolic Business. It had also lifted the sales force by 50% for BELVIQ to about 600. The addition of sales force would allow the company to extend its reach to cover about 92K physicians in the U.S.<\/p>\n<p style=\"text-align: justify;\">The U.S. Food and Drug Administration had earlier given its approval for Arena\u2019s BELVIQ to be used with a reduced calorie diet besides more physical activity for the unending management of weight in adult patients. It is believed to cut consumption of food and also promote satiety through selective activation of serotonin 2C receptors in the brain.<\/p>\n<p style=\"text-align: justify;\"><b>2Q Results<\/b><\/p>\n<p style=\"text-align: justify;\">Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)\u00a0had reported net income of $7.5 million or 3 cents a share for the second quarter, sharply down from $40.1 million or 18 cents a share in the year-ago quarter. Revenues also plummeted to $12.8 million from $68.93 million in the previous year quarter. While net product sales jumped to $3.53 million from $1.32 million, Eisai collaborative revenue plunged to $8.55 million from $66.46 million in the year earlier quarter. Revenue from manufacturing services also fell to $578K from $973K in the same quarter last year.<\/p>\n<p style=\"text-align: justify;\">Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)\u2019s research and development expenses jumped to $27.03 million from $18.83 million in the 2013-second quarter. It closed the quarter with cash and cash equivalents of $200.8 million.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 08\/05\/2014 (wallstreetpr) \u2013\u00a0Biopharmaceutical company Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) disclosed that it had witnessed encouraging advancements of BELVIQ commercialization with the prescriptions recording a [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":17597,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2717,2718],"stock_ticker":[],"class_list":["post-27533","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-arena-pharmaceuticals-inc-nasdaqarna","tag-nasdaqarna","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Sees Encouraging Advancements Of BELVIQ - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Sees Encouraging Advancements Of BELVIQ - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 08\/05\/2014 (wallstreetpr) \u2013\u00a0Biopharmaceutical company Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) disclosed that it had witnessed encouraging advancements of BELVIQ commercialization with the prescriptions recording a [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-08-05T15:37:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Arena-Pharmaceuticals-Inc..png\" \/>\n\t<meta property=\"og:image:width\" content=\"550\" \/>\n\t<meta property=\"og:image:height\" content=\"350\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Alan Masterson\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alan Masterson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533\"},\"author\":{\"name\":\"Alan Masterson\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\"},\"headline\":\"Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Sees Encouraging Advancements Of BELVIQ\",\"datePublished\":\"2014-08-05T15:37:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533\"},\"wordCount\":337,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Arena-Pharmaceuticals-Inc..png\",\"keywords\":[\"Arena Pharmaceuticals Inc (NASDAQ:ARNA)\",\"NASDAQ:ARNA\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533\",\"name\":\"Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Sees Encouraging Advancements Of BELVIQ - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Arena-Pharmaceuticals-Inc..png\",\"datePublished\":\"2014-08-05T15:37:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Arena-Pharmaceuticals-Inc..png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Arena-Pharmaceuticals-Inc..png\",\"width\":550,\"height\":350,\"caption\":\"Arena-Pharmaceuticals-Inc.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Sees Encouraging Advancements Of BELVIQ\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\",\"name\":\"Alan Masterson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"caption\":\"Alan Masterson\"},\"description\":\"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Sees Encouraging Advancements Of BELVIQ - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533","og_locale":"en_US","og_type":"article","og_title":"Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Sees Encouraging Advancements Of BELVIQ - Wall Street PR","og_description":"Boston, MA 08\/05\/2014 (wallstreetpr) \u2013\u00a0Biopharmaceutical company Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) disclosed that it had witnessed encouraging advancements of BELVIQ commercialization with the prescriptions recording a [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-08-05T15:37:43+00:00","og_image":[{"width":550,"height":350,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Arena-Pharmaceuticals-Inc..png","type":"image\/png"}],"author":"Alan Masterson","twitter_misc":{"Written by":"Alan Masterson","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533"},"author":{"name":"Alan Masterson","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90"},"headline":"Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Sees Encouraging Advancements Of BELVIQ","datePublished":"2014-08-05T15:37:43+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533"},"wordCount":337,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Arena-Pharmaceuticals-Inc..png","keywords":["Arena Pharmaceuticals Inc (NASDAQ:ARNA)","NASDAQ:ARNA"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533","url":"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533","name":"Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Sees Encouraging Advancements Of BELVIQ - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Arena-Pharmaceuticals-Inc..png","datePublished":"2014-08-05T15:37:43+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Arena-Pharmaceuticals-Inc..png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Arena-Pharmaceuticals-Inc..png","width":550,"height":350,"caption":"Arena-Pharmaceuticals-Inc."},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/arena-pharmaceuticals-inc-nasdaqarna-sees-encouraging-advancements-of-belviq-27533#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Sees Encouraging Advancements Of BELVIQ"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90","name":"Alan Masterson","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","caption":"Alan Masterson"},"description":"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/27533","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=27533"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/27533\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/17597"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=27533"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=27533"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=27533"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=27533"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}